Cerus Reports Strong Preliminary 2025 Revenue, Guides for 9-11% Growth in 2026
Summary
Cerus reported strong preliminary 2025 product revenue and issued positive 2026 guidance, indicating continued growth and upcoming product development milestones.
Key Events
-
Preliminary 2025 Revenue Growth
Cerus reported preliminary Q4 2025 product revenue of $57.8 million, a 14% increase year-over-year, and full-year 2025 product revenue of $206.1 million, also up 14% from 2024.
-
Positive 2026 Revenue Guidance
The company expects full-year 2026 product revenue to be between $224 million and $228 million, representing 9%-11% year-over-year growth.
-
Strong IFC Product Performance
INTERCEPT Fibrinogen Complex (IFC) revenue showed significant growth, contributing $16.7 million to full-year 2025 revenue (up approximately 80%) and is projected to grow 20-30% in 2026.
-
Upcoming Product Milestones
Cerus anticipates submitting a Premarket Approval (PMA) application for its next-generation INT200 device in mid-2026 and expects Phase 3 RedeS study results for Red Blood Cells in the second half of 2026.
Analysis
Cerus Corporation announced robust preliminary product revenue for both the fourth quarter and full-year 2025, demonstrating significant year-over-year growth. The company also provided a positive outlook for 2026, projecting continued revenue expansion. This strong performance, coupled with anticipated key product development and clinical milestones, suggests a positive trajectory for the company's market position and future growth prospects, providing investors with a clear view of operational momentum.
At the time of this filing, CERS was trading at $2.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $401.5M. The 52-week trading range was $1.12 to $2.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.